文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

非小细胞肺癌。

Non-small cell lung cancer.

机构信息

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

出版信息

J Natl Compr Canc Netw. 2012 Oct 1;10(10):1236-71. doi: 10.6004/jnccn.2012.0130.


DOI:10.6004/jnccn.2012.0130
PMID:23054877
Abstract

Most patients with non-small cell lung cancer (NSCLC) are diagnosed with advanced cancer. These guidelines only include information about stage IV NSCLC. Patients with widespread metastatic disease (stage IV) are candidates for systemic therapy, clinical trials, and/or palliative treatment. The goal is to identify patients with metastatic disease before initiating aggressive treatment, thus sparing these patients from unnecessary futile treatment. If metastatic disease is discovered during surgery, then extensive surgery is often aborted. Decisions about treatment should be based on multidisciplinary discussion.

摘要

大多数非小细胞肺癌(NSCLC)患者被诊断为晚期癌症。本指南仅包含关于 IV 期 NSCLC 的信息。广泛转移疾病(IV 期)的患者是全身治疗、临床试验和/或姑息治疗的候选者。其目标是在开始积极治疗之前确定患有转移性疾病的患者,从而使这些患者免受不必要的无效治疗。如果在手术过程中发现转移疾病,则通常会中止广泛的手术。关于治疗的决策应基于多学科讨论。

相似文献

[1]
Non-small cell lung cancer.

J Natl Compr Canc Netw. 2012-10-1

[2]
Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw. 2024-5

[3]
Non-small cell lung cancer.

J Natl Compr Canc Netw. 2010-7

[4]
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2010-5

[5]
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

J Clin Oncol. 2017-8-14

[6]
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw. 2017-4

[7]
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2018-10-1

[8]
Plain language summary and patient perspective of the American Society for Clinical Oncology guideline: management of stage 3 non-small-cell lung cancer.

Future Oncol. 2024

[9]
SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015.

Clin Transl Oncol. 2015-12

[10]
Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay.

Future Oncol. 2021-12

引用本文的文献

[1]
The value of chromosome 8 heteroploid tumor cells in the peripheral blood and pleural effusion in evaluating treatment efficacy and the prognosis of metastatic non-small cell lung cancer patients.

J Thorac Dis. 2025-5-30

[2]
Immunological biomarkers and gene signatures predictive of radiotherapy resistance in non-small cell lung cancer.

Front Immunol. 2025-5-29

[3]
Prognostic factors of survival in patients with lung cancer after low-dose computed tomography screening: a multivariate analysis of a lung cancer screening cohort in China.

BMC Cancer. 2025-4-9

[4]
Synergistic Effect of HAD-B1 and Osimertinib Against Gefitinib Resistant HCC827 Non-Small Cell Lung Cancer Cells.

Integr Cancer Ther. 2025

[5]
Osimertinib in Early-Stage EGFR-Mutated Non-small Cell Lung Cancer: A Narrative Review of Its Impact on Survival, Safety, and Clinical Outcomes.

Cureus. 2024-11-1

[6]
Discovery of -substituted-2-oxoindolin benzoylhydrazines as c-MET/SMO modulators in EGFRi-resistant non-small cell lung cancer.

RSC Med Chem. 2024-10-3

[7]
Predictive value of metabolic parameters and apparent diffusion coefficient derived from 18F-FDG PET/MR in patients with non-small cell lung cancer.

BMC Med Imaging. 2024-10-29

[8]
Clinicopathologic and prognostic implications of HOXA gene and its associated long-noncoding RNAs expression in non-small cell carcinoma: A meta-analysis.

Medicine (Baltimore). 2024-8-9

[9]
Polydatin, a potential NOX5 agonist, synergistically enhances antitumor activity of cisplatin by stimulating oxidative stress in non‑small cell lung cancer.

Int J Oncol. 2024-8

[10]
Nintedanib in Combination With Chemotherapy in the Treatment of Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Cureus. 2024-2-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索